Indiplon Approval Status
Indiplon is a novel pyrazolopyrimidine sedative-hypnotic agent intended for use in the treatment of insomnia.
In December 2007, Neurocrine Biosciences, Inc. announced the receipt of an Approvable Letter from the U.S. Food and Drug Administration (FDA) advising the company that the New Drug Application (NDA) for Indiplon was approvable pending additional clinical and preclinical data. Neurocrine has since decided to discontinue all clinical and marketing development of Indiplon in the United States.
Development Status and FDA Approval Process for Indiplon
|Dec 13, 2007||Neurocrine Receives Approvable Letter for Indiplon Capsules with
Additional Safety and Efficacy Data Required by FDA|
|Aug 22, 2007||Neurocrine Announces PDUFA Action Date of December 12, 2007 for
|Jun 13, 2007||Neurocrine Announces Resubmission of New Drug Application for
|Sep 5, 2006||Neurocrine Reports Results of FDA End-of-Review Meeting on Indiplon Capsules NDA|
|Jun 15, 2006||Neurocrine Completes Review of Indiplon Action Letters|
|May 16, 2006||Neurocrine Receives Approvable Letter for indiplon Capsules and Non-Approvable for indiplon Tablets for the Treatment of Insomnia|
|Jul 26, 2005||Neurocrine Announces Acceptance of New Drug Application for Indiplon Tablets|
|Jun 14, 2005||Neurocrine Announces Acceptance of New Drug Application for Indiplon Capsules|
|May 26, 2005||Neurocrine Announces Submission of New Drug Application for Indiplon Tablets|
|Apr 14, 2005||Neurocrine Announces Submission of New Drug Application for Indiplon Capsules|
|Feb 7, 2005||Neurocrine Biosciences Announces Resubmission Status of Indiplon|
|Jan 11, 2005||Neurocrine Biosciences Announces Plans to Resubmit Indiplon Modified Release New Drug Application (NDA)|
|Dec 21, 2004||Indiplon IR NDA (New Drug Application) to Be Reformatted Due to Difficulties in Accessing Portions of the Electronic NDA|
|Nov 22, 2004||Neurocrine Submits New Drug Application (NDA) for Indiplon Modified Release Tablets for the Treatment of Insomnia|
|Oct 19, 2004||Neurocrine Submits New Drug Application (NDA) for Indiplon Immediate Release Capsules for the Treatment of Insomnia|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.